Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | IL2 | P60568 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8488526 | 0.80 | KDM4E (0.51) | KDM4EHRH3HTTLMNAMAPT | |
| SCHEMBL342910 | 0.79 | KDM4E (0.59) | KDM4EHRH3HTTLMNAMAPT | |
| SCHEMBL471881 | 0.78 | KDM4E (0.62) | KDM4EHRH3HTTLMNAMAPT | |
| Hydrochloric Acid SCHEMBL11553058 | 0.78 | KDM4E (0.58) | KDM4EHRH3HTTLMNAMAPT | |
| SCHEMBL471858 | 0.77 | KDM4E (0.60) | KDM4EHRH3HTTLMNAMAPT | |
| Hydrochloric Acid SCHEMBL4777692 | 0.76 | KDM4E (0.56) | KDM4EHRH3HTTLMNAMAPT | |
| SCHEMBL10837608 | 0.76 | KDM4E (0.56) | KDM4EHRH3HTTLMNAMAPT | |
| Hydrochloric Acid SCHEMBL4777694 | 0.76 | KDM4E (0.56) | KDM4EHRH3HTTLMNAMAPT | |
| SCHEMBL20410843 | 0.75 | KDM4E (0.59) | KDM4EHRH3HTTLMNAMAPT | |
| SCHEMBL4792824 | 0.74 | HRH3 (0.43) | KDM4EHRH3HTTLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | claimed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | claimed |
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| CN-1070173-C | Benzoylguanidine derivatives as medicaments | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-08-29 | — | — | CN | disclosed |
| CN-1158606-A | Benzoylguanidine derivatives as medicaments | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-09-03 | — | — | CN | disclosed |
| CN-1022184-C | Process for preparing (1 H-imidzol-1-ylmethyl) substituted benzotriazole derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1993-09-22 | — | — | CN | disclosed |
| EP-0293978-B1 | (1H-AZOL-1-YLMETHYL)SUBSTITUTED BENZOTRIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-09-15 | — | — | EP | disclosed |
| CN-88103408-A | Process for preparing (1H-oxazol-1-ylmethyl) substituted benzotriazole derivatives | — | 1988-12-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | KDM4E 2328/4885HRH3 4562/4885HTT 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.